Glimigen-MV1 Tablet

By Glimigen-MV

Rx

10 Tablet in a Strip

Composition icon

Composition

Glimepiride(1mg) + Metformin(500mg) + Voglibose(0.2mg)

Manufacturer - Ekard Life Sciences Pvt Ltd icon

Manufacturer - Ekard Life Sciences Pvt Ltd

# 7-1-497, Monda Market Bandimetta Secunderabad Hyderabad,Telangana-500003 India

Expires on or after icon

Expires on or after

August, 2025

About Glimigen-MV1 Tablet

Glimigen-MV1 Tablet is a medication that falls under the category of anti-diabetic drugs and is specifically designed to treat type 2 diabetes mellitus in adults. This chronic condition affects how the body processes glucose, leading to increased blood sugar levels and various symptoms like frequent urination, increased thirst, and hunger. The tablet contains a combination of three main antidiabetic drugs: Glimepiride, Metformin, and Voglibose. Glimepiride, a 'sulfonylurea', works by boosting the insulin release from the pancreas, while Metformin helps in decreasing the glucose production by the liver and increasing insulin sensitivity in the body. By working together, these components help in preventing high spikes in blood sugar levels and effectively managing diabetes.

It is crucial to take Glimigen-MV1 Tablet with food to avoid any stomach discomfort. Your doctor will determine the appropriate dosage and duration of treatment based on your individual medical condition and response to the medication. While taking this medication, common side effects may include low blood glucose levels (hypoglycemia), taste changes, nausea, diarrhea, stomach pain, headaches, and upper respiratory symptoms. Most of these side effects are mild and tend to fade away gradually. However, if you experience persistent side effects, it is important to consult your doctor for further guidance.

It is essential not to discontinue Glimigen-MV1 Tablet abruptly without consulting your doctor, as this can lead to an increase in blood sugar levels, putting you at risk for complications such as damage to the eyes, kidneys, and nerves. Individuals with type 1 diabetes mellitus or severe kidney or liver disease should avoid taking this medication. Inform your doctor if you have any heart conditions, are pregnant, or breastfeeding before starting Glimigen-MV1 Tablet. Regular monitoring of blood sugar levels and periodic blood tests may be recommended by your doctor to ensure the medication's effectiveness and safety for your health.


Benefits

Glimigen-MV1 Tablet offers multiple benefits for individuals with Type 2 diabetes mellitus. This medication plays a crucial role in managing high blood glucose levels, which are common in diabetes. By slowing down the breakdown of food in the intestine into simple glucose, it helps in reducing the spike in blood glucose levels after meals. Moreover, Glimigen-MV1 Tablet facilitates the elimination of excess glucose through urine, thereby aiding in maintaining optimal blood glucose levels.


Controlling blood glucose levels is vital in diabetes management as it significantly reduces the risk of developing serious complications associated with the condition, such as kidney damage, eye problems, nerve issues, and even limb amputation. Additionally, for individuals with Type 2 diabetes and existing cardiovascular disease, this medication can lower the risk of mortality from heart-related issues.


To maximize the benefits of Glimigen-MV1 Tablet, it is recommended to use it consistently in combination with a balanced diet and regular exercise routine. By adhering to the prescribed treatment plan, individuals can lead a normal and healthy life while safeguarding their future well-being. It is essential to continue using the medication for the duration prescribed by healthcare providers to ensure ongoing protection and maintenance of overall health.


How to use the Glimigen-MV1 Tablet

To use Glimigen-MV1 Tablet, follow your doctor's instructions on dosage and duration. Swallow the tablet whole without chewing, crushing, or breaking it. It is recommended to take Glimigen-MV1 Tablet on an empty stomach for best results. Make sure to adhere to your doctor's guidance carefully for optimal effectiveness of the medication.


Uses of Glimigen-MV1 Tablet

Glimigen-MV1 Tablet is primarily used for the treatment of Type 2 diabetes mellitus. This medication is specifically formulated to help manage blood sugar levels in individuals with this type of diabetes. It works by regulating the levels of insulin and blood sugar in the body, thereby assisting in controlling the symptoms of Type 2 diabetes mellitus. Glimigen-MV1 Tablet is commonly prescribed by healthcare professionals to improve glycemic control in patients with Type 2 diabetes mellitus.


What conditions Glimigen-MV1 Tablet treats?

Glimigen-MV1 Tablet is used for treating type 2 diabetes mellitus in adults. It helps to control blood sugar levels and reduce the risk of complications such as kidney damage, eye problems, nerve issues, and limb loss. Remember, it's important to take this medicine consistently with food and not to stop it suddenly without your doctor's advice, as doing so could lead to high blood sugar levels and serious health risks. Along with medication, following a healthy lifestyle with a balanced diet and regular exercise is crucial in managing diabetes effectively.


Should you consult a doctor?

It is important to seek medical advice if you experience any severe side effects while taking Glimigen-MV1 Tablet. If you notice symptoms such as severe allergic reactions, difficulty breathing, swelling of the face, lips, tongue or throat, or signs of liver problems like dark urine, yellowing of eyes or skin, it is crucial to consult your doctor immediately. Additionally, if you experience symptoms of low blood glucose levels (hypoglycemia) such as confusion, seizures, unconsciousness, or if you are unable to manage your blood sugar levels effectively, seek medical help promptly. If you develop any new or worsening symptoms that are concerning or persistent, it is recommended to contact your healthcare provider for guidance. Remember to always communicate with your doctor about any changes in your health condition or any unusual reactions to the medication.


Side effects of Glimigen-MV1 Tablet

When taking Glimigen-MV1 Tablet, you may experience certain side effects. Some of the common side effects include nausea, diarrhea, abdominal pain, hypoglycemia (low blood glucose level), and loss of appetite. These side effects are usually mild and temporary, as your body gets used to the medication. However, if these side effects persist or cause concern, it is important to consult your doctor. They can provide guidance on how to manage these side effects or adjust your treatment if necessary. Remember, everyone reacts differently to medications, so what one person experiences may not be the same for another.


Safety advice

scroll

liver

Glimigen-MV1 Tablet needs to be used carefully in individuals with liver problems. It might be necessary to adjust the dose of Glimigen-MV1 Tablet, so it is essential to seek advice from your doctor. Usually, Glimigen-MV1 Tablet is initially prescribed in smaller amounts for individuals with mild to moderate liver disease. However, it is advisable to avoid using this medication in cases of severe liver disease.

scroll

kidney

Glimigen-MV1 Tablet may not be safe for patients with kidney disease and is not recommended, especially for those with severe kidney issues. Please consult your doctor before using.

scroll

alcohol

It is not safe to drink alcohol while taking Glimigen-MV1 Tablet.

scroll

driving

Caution - Driving Your ability to drive may be impacted if your blood sugar levels are too low or too high. Avoid driving if you experience these symptoms.

scroll

pregnancy

Glimigen-MV1 Tablet may be unsafe during pregnancy. Animal studies indicate potential harm to the developing baby. Your doctor will assess benefits and risks before prescribing. Please consult your doctor before use.

scroll

breastfeeding

Using Glimigen-MV1 Tablet while breastfeeding may not be safe. Limited data indicates that the medication could enter breastmilk and potentially harm the baby.


Consumption warning before consuming Glimigen-MV1 Tablet

Before consuming Glimigen-MV1 Tablet, it's important to note the following warnings. Always take this medication with food at the same time each day as prescribed by your doctor. Do not discontinue usage without consulting your doctor, as this could lead to a rise in blood sugar levels and potential risks such as kidney damage, blindness, nerve problems, and limb loss.


Remember, Glimigen-MV1 Tablet is just one part of a comprehensive treatment plan for diabetes that should also include a healthy diet, regular exercise, and weight management. Common side effects include low blood glucose levels, so be aware of symptoms like sweating, dizziness, and headache. It's crucial to have a fast-acting glucose source on hand and avoid alcohol consumption to prevent hypoglycemia risks. Other potential side effects may include taste changes, nausea, diarrhea, and weight gain.


Avoid taking Glimigen-MV1 Tablet if you have type 1 diabetes, diabetic ketoacidosis, severe kidney or liver disease, or a history of heart conditions. Pregnant or breastfeeding women should consult their doctor before use. Regular monitoring of blood sugar levels and necessary blood tests are essential while taking this medication.


What if you forgot to take Glimigen-MV1 Tablet?

If you accidentally skip a dose of Glimigen-MV1 Tablet, try to take it as soon as you remember. But if it's almost time for your next scheduled dose, it's better to skip the missed one and continue with your regular dosing schedule. Remember, do not take a double dose to make up for the missed one. It's important to stay consistent with your medication routine to ensure its effectiveness.


Related lab tests

For patients taking Glimigen-MV1 Tablet, there are certain related lab tests that may be important to monitor their health. These tests can help healthcare providers assess how the medication is affecting the body and ensure the patient's overall well-being.


1. Glucose - Fasting Blood Test: This test measures the levels of glucose in the blood after a period of fasting. It is used to diagnose diabetes and monitor blood sugar control in patients with diabetes.


2. Glucose - Postprandial Blood Test: A postprandial blood glucose test measures the blood sugar levels after a meal. This test helps in evaluating how the body processes glucose after eating and provides important information about blood sugar control.


3. Glycosylated Hemoglobin (HbA1c): The glycosylated hemoglobin test, also known as the HbA1c test, measures the average blood sugar levels over the past 2-3 months. It is an essential test for monitoring long-term blood sugar control in patients with diabetes.


Regular monitoring of these lab tests can provide valuable insights into the effects of Glimigen-MV1 Tablet on blood sugar levels and help healthcare providers make informed treatment decisions.


Additional Information

Habit FormingNo
Chemical Class-
Therapeutic ClassANTI DIABETIC
Action Class-

FAQs


Disclaimer

The information provided on this website is to the best of our abilities to ensure it is accurate, reliable, and reviewed by a team of professionals. It should not be used to diagnose, prevent, or cure any health problem. The information presented here is not intended to create a doctor-patient relationship or replace a registered medical practitioner's advice, diagnosis, or treatment. The absence or provision of any information or warning regarding any medicine should not be assumed as an implied or explicit assurance of safety or efficacy. We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition. Do not ignore professional medical advice or delay seeking it based on the content encountered on our website. We intend to support, not replace, the doctor-patient relationship.

95

Inclusive of all taxes

Content verified by

chevron-right

Dr. Gowri Kulkarni

MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)

Last update on 01-Oct-2024